Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ovarian Function Suppression + Aromatase Inhibitor|DRUG: Adjuvant Chemotherapy + Ovarian Function Suppression
Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)